Shenzhen Hepalink Pharmaceutical Co (002399.SZ) Chairman and founder Li Li’s wealth rose to $7.8 billion after the shares gained as much as 27% on China’s Nasdaq-style market for start-up stocks.
Category: Health Care
After being rejected by state-owned companies, Li Li is now worth $7.8 billion
Source: medicine.people.com.cn
Categories
Charles River to buy WuXi PharmaTech
Charles River Laboratories International (CRL.NYSE) has agreed to buy China’s WuXi PharmaTech (WX.NYSE) for US$1.6 billion in what is set to become the largest foreign takeover of a Chinese company, Bloomberg reported. The acquisition would give the US firm a foothold in the Chinese market, where revenue from drug-testing services is growing by up to […]
Source: news.163.com